56 / 69
56
15.
Vaz de Campos MG, Montesano FT, Rodrigues MM,
Chauffaille M de L. Clinical implications of der(9q)
deletions detected through dual-fusion fluorescence in
situ hybridization in patients with chronic myeloid
leukemia. Cancer Genet Cytogenet 2007;178:49-56.
16.
Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini
M, Gugliotta G, et al. Variant Philadelphia translocations:
molecular-cytogenetic characterization and prognostic
influence on frontline imatinib therapy, a GIMEMA
Working Party on CML analysis. Blood 2011;117:6793-800.
17.
Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini
M, Kerim S, et al. Deletions of the derivative chromosome
9 do not influence the response and the outcome of chronic
myeloid leukemia in early chronic phase treated with
imatinib mesylate: GIMEMA CML Working Party
analysis. J Clin Oncol 2010;28:2748-54.
18.
Landstrom AP, Knudson RA, Dewald GW, Ketterling RP,
Tefferi A. Philadelphia chromosome mosaicism at
diagnosis in chronic myeloid leukemia: clinical correlates
and effect on imatinib mesylate treatment outcome. Leuk
Lymphoma 2007;48:2137-40.
19.
Gorusu M, Benn P, Li Z, Fang M. On the genesis and
prognosis of variant translocations in chronic myeloid
leukemia. Cancer Genet Cytogenet 2007;173:97-106.
20.
Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A,
Fekete S, et al. Additional chromosome abnormalities,
BCR-ABL tyrosine kinase domain mutations and clinical
outcome in Hungarian tyrosine kinase inhibitor-resistant
chronic myelogenous leukemia patients. Acta Haematol
2012; 127:34-42.
21.
Kim TD, Türkmen S, Schwarz M, Koca G, Nogai H,
Bommer C, et al. Impact of additional chromosomal
aberrations and BCR-ABL kinase domain mutations on the